Get the Stockscreener App
2.62
6.09%
-0.17
After Hours:
2.62
Polaryx Therapeutics Inc stock is traded at $2.62, with a volume of 58,067.
It is down -6.09% in the last 24 hours and down -83.62% over the past month.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small molecule drug candidates designed to address core pathological mechanisms common to LSDs.
See More
Previous Close:
$2.79
Open:
$2.72
24h Volume:
58,067
Relative Volume:
0.06
Market Cap:
$124.04M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-17.87%
1M Performance:
-83.62%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.62
$2.8047
1-Week Range:
$2.62
$3.41
52-Week Range:
$2.201
$33.90
Polaryx Therapeutics Inc Stock (PLYX) Company Profile
Name
Polaryx Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare PLYX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLYX
Polaryx Therapeutics Inc
|
2.62 | 132.09M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Polaryx Therapeutics Inc Stock (PLYX) Latest News
Polaryx Therapeutics (PLYX) Insider Trading Activity 2026 - MarketBeat
Polaryx Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | PLYX | US73110F1003 - marketscreener.com
Polaryx commits to patients with rare pediatric lysosomal storage disorders - TipRanks
Polaryx Therapeutics Inc (PLYX) Stock Price, Quote, News & History - Benzinga
Maxim starts Polaryx at Buy, sees PLX-200 as differentiated - TipRanks
PLYX | Polaryx Therapeutics, Inc. Common Analyst Forecasts - Quiver Quantitative
Polaryx Therapeutics, Inc.Common Stock (NQ: PLYX - The Chronicle-Journal
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders - Bitget
PLYX | Polaryx Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Mstone Partners Healthcare Highlights Polaryx Therapeutics’ Latest Preclinical Data Shared at WORLDSymposium™ - EIN News
Polaryx Therapeutics (PLYX) 10K Form and SEC Filings 2026 - MarketBeat
Polaryx Therapeutics (PLYX) Stock Forecast and Price Target 2026 - MarketBeat
Polaryx Therapeutics (PLYX) Stock Price, News & Analysis - MarketBeat
Top Polaryx Therapeutics (PLYX) Competitors 2026 - MarketBeat
Polaryx Therapeutics (PLYX) Stock Trends and Sentiment 2026 - MarketBeat
Insider Buying: G. Landis Acquires Shares of Polaryx Therapeutics Inc (PLYX) - GuruFocus
PLYX Stock Price, News & Analysis - Stock Titan
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
What's Going On With Polaryx Therapeutics Stock Wednesday? - Benzinga
Dow Gains 100 Points; Analog Devices Posts Upbeat Q1 Earnings - Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Polaryx selects CRO for phase 2 trial of rare disease treatment - Investing.com South Africa
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans - Bitget
SMJ INTERNATIONAL HOLDINGS INC. (SMJF) Stock, Price, News, Quotes, Forecast and Insights - MSN
Polaryx Therapeutics Surges Amid Strategic Market Moves - StocksToTrade
Polaryx Therapeutics Sees Strategic Moves Amid Market Volatility - timothysykes.com
Polaryx selects CRO for Soteria Phase 2 trial - TipRanks
Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial - The Manila Times
Polaryx Therapeutics selects contract research organization for Soteria phase 2 basket trial - marketscreener.com
Rare-disease biotech readies Phase 2 trial across four childhood disorders - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
FORTUNE BRANDS INNOVATIONS, INC. (FBIN) Stock, Price, News, Quotes, Forecast and Insights - MSN
Polaryx Therapeutics, Inc. Rings the Closing Bell - Nasdaq
Polaryx Therapeutics, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
NUSCALE POWER CORPORATION (SMR) Stock, Price, News, Quotes, Forecast and Insights - MSN
Polaryx to evaluate PLX-200 for Krabbe disease in Phase 2 trial - Investing.com South Africa
Polaryx announces pre-clinical data related to Soteria - TipRanks
Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ - The Manila Times
In mice with Krabbe disease, Polaryx drug restored movement, extended life - Stock Titan
Dow Falls 250 Points; Becton Dickinson Posts Upbeat Earnings - Benzinga
Morning Market Movers: UOKA, KD, HIMS, PGY See Big Swings - RTTNews
Strategy, Bitmine Immersion Technologies And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Why STMicroelectronics Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Finance Watch: Four IPOs In One Week - Citeline News & Insights
Polaryx appoints Mitchel Berger, Francis Braun, Charles Ryan to board - TipRanks
Polaryx Therapeutics (PLYX) Valuation Check After Sharp Single Day Share Price Decline - simplywall.st
Cerence Inc. (CRNC) - MSN
Eli Lilly and Oracle among market cap stock movers on Thursday - Investing.com
Polaryx Therapeutics, Inc. Announces Board Changes, Effective January 29, 2026 - marketscreener.com
Polaryx Therapeutics Inc Stock (PLYX) Financials Data
There is no financial data for Polaryx Therapeutics Inc (PLYX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):